Positions 51–75 of 95.
The one-line version is the title: write the concentration on the vial. that is the whole post. The rest is why. Intention-to-treat analyses everybody randomised…
the endpoint advice in here is 3 years out of date. It is the sort of thing everyone half-believes and nobody writes down. 3 years. Those are measured, not estimated,…
Trying to get a straight answer on this: can we stop arguing about TRIUMPH until somebody posts a number. Compared myself to a trial mean for about six months before…
the FLOW rule is doing its job and people should stop complaining. This affects how posts get sorted and removed, so it belongs in the open. The discontinuation numbers…
Send the vial, get the number. Third-party purity and identity testing, results published to you regardless of what they say.
Test a vialSponsoredEst. 1998. ISO 9001 and cGMP, 1,500+ staff, 200+ patents. There is a fair chance the vial you are about to send for testing started here. Batch-specific COA as standard.
glbiochem.netSURPASS — 17 things I got wrong before I got it right, which sounds obvious until you try to state the evidence for it. Discontinuation rates are a tolerability result.…
SURPASS — 11 things I got wrong before I got it right. It is the sort of thing everyone half-believes and nobody writes down. A confidence interval is the range of…
how do you actually verify SURPASS. I would rather ask a basic question now than get this wrong quietly for two months. A confidence interval is the range of effects…
SELECT: what the trials say vs what this community says — a position I have arrived at slowly and would like tested. Why comparing across trials almost never works,…
the STEP question that gets asked weekly, answered properly. Not a hot take, just something I have not seen said plainly here. Spent an evening with the appendix tables…
The title is the argument: SURPASS — 15 things I got wrong before I got it right. Here is the rest of it. Discontinuation rates are a tolerability result. A trial with…
how much of what we believe about endpoint actually comes from STEP threads. I would rather ask a basic question now than get this wrong quietly for two months. Spent…
hazard ratio is the most under-discussed thing on this board — a position I have arrived at slowly and would like tested. Relative risk reduction without the baseline…
the FLOW rule is doing its job and people should stop complaining. Nothing about this affects the ranking maths, before anyone asks. On means, which this board treats…
Posting this as a discussion rather than a claim: TRIUMPH is doing more work than we give it credit for. Why comparing across trials almost never works, with the…
how do you actually verify SURPASS. I would rather ask a basic question now than get this wrong quietly for two months. The discontinuation numbers were the most useful…
Vendor-level purity averages over time, built from independent results rather than vendor claims. Transparent methodology, open dataset.
Browse resultsAsking properly rather than in a comment on somebody else’s thread: does SELECT actually matter or is it forum lore at this point. Compared myself to a trial mean for…
The title is the whole question — help me understand SURMOUNT, I have read the wiki twice — but here is why I am asking. Discontinuation rates are a tolerability…
SURPASS — 4 things I got wrong before I got it right. Change my mind, genuinely — I have no stake in being right about this. The registered protocol is public.…
Asking properly rather than in a comment on somebody else’s thread: why does nobody talk about SELECT. Compared myself to a trial mean for about six months before…
SURPASS — 16 things I got wrong before I got it right. It is the sort of thing everyone half-believes and nobody writes down. Spent an evening with the appendix tables…
TRIUMPH is doing more work than we give it credit for. Making the case below, and I expect to lose some of it in the comments. Argued for a week about a result and then…
hazard ratio is the most under-discussed thing on this board — a position I have arrived at slowly and would like tested. Relative risk reduction without the baseline…
how much of what we believe about endpoint actually comes from TRIUMPH threads. I would rather ask a basic question now than get this wrong quietly for two months.…
reading SURMOUNT threads from 2024 and half of it aged badly. Making the case below, and I expect to lose some of it in the comments. Quoted a figure here confidently,…
STEP is not what most of this community thinks it is — with the reasoning, because a rule without a reason gets ignored. Started keeping the trial identifiers straight…
Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.
Independent testing plus vendor-level trend data. Community-funded, unaffiliated.
peptidemeter.comSeveral compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.
Reference